Massimo Breccia | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
The Platelet COUNT at Diagnosis of Essential Thrombocythemia Is a Prognostic Factor for Thrombosis-Free Survival: Retrospective Analysis on 1201 Patients	BLOOD	2015
ROLE OF TREATMENT ON THE DEVELOPMENT OF SECONDARY MALIGNANCIES IN PATIENTS WITH ESSENTIAL THROMBOCYTEMIA	HAEMATOLOGICA	2015
SPLEEN ENLARGEMENT IS A RISK FACTOR FOR THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA: EVALUATION ON 1097 PATIENTS AND VALIDATION ON 792 PATIENTS	HAEMATOLOGICA	2015
ROLE OF TREATMENT ON THE DEVELOPMENT OF SECONDARY MALIGNANCIES IN PATIENTS WITH ESSENTIAL THROMBOCYTEMIA	HAEMATOLOGICA	2015
Erythropoietin treatment in patients with myelodysplastic syndromes and type 2 diabetes.	JOURNAL OF DIABETES	2015
Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients.	AMERICAN JOURNAL OF HEMATOLOGY	2015
Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib.	AMERICAN JOURNAL OF HEMATOLOGY	2015
PULMONARY INFECTIONS IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA RECEIVING AZACITIDINE TREATMENT	HAEMATOLOGICA	2015
PREDICTORS OF DEEP MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH IMATINIB MESYLATE: AN ANALYSIS BY THE GIMEMA CML WP	HAEMATOLOGICA	2015
DEEP MOLECULAR RESPONSE TO NILOTINIB AS FIRST-LINE TREATMENT OF BCR-ABL plus CML	HAEMATOLOGICA	2015
A POPULATION-BASED STUDY OF MYELODYSPLASTIC SYNDROMES PATIENTS IN THE LAZIO REGION (ITALY), MISCODING IN MEDICAL CLAIMS AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY	HAEMATOLOGICA	2015
UNFAVORABLE KARYOTYPE AND MOLECULAR NEGATIVITY SIGNIFICANTLY INFLUENCE THE INFECTIOUS RISK IN MYELOFIBROSIS: EVALUATION ON 426 PATIENTS	HAEMATOLOGICA	2015
DASATINIB FIRST-LINE: UPDATE DI UNA ESPERIENZA "REAL-LIFE" ITALIANA	HAEMATOLOGICA	2015
INFECTIOUS RISK IN MYELOFIBROSIS: EVALUATION ON 426 PATIENTS	HAEMATOLOGICA	2015
Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response	BLOOD	2015
Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial	BLOOD	2015
VERY ELDERLY CP-CML PATIENTS TREATED WITH IMATINIB FRONTLINE: HAVE CONCOMITANT THERAPIES AN IMPACT ON OUTCOME AND TOXICITY?	HAEMATOLOGICA	2015
APPLICATION OF CARDIOVASCULAR RISK ASSESSMENT IN CHRONIC PHASE CML PATIENTS TREATED WITH NILOTINIB ALLOWS IDENTIFICATION OF SUBJECTS AT HIGH RISK OF EVENTS	HAEMATOLOGICA	2015
ACCURACY OF PHYSICIAN ASSESSMENT OF TREATMENT PREFERENCES AND HEALTH STATUS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES	HAEMATOLOGICA	2015
PULMONARY INFECTIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES RECEIVING AZACYTIDINE TREATMENT	HAEMATOLOGICA	2015